Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449029 · ClinicalTrials.gov registry record · Phase 2
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 457
- Enrollment target
NCT04449029 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 457 participants.
The verdict
NCT04449029, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 457 participants
- Enrollment target
Study Summary
Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide therapy. This study is intended to evaluate if treatment with GSK3228836 can achieve sustained virologic response (SVR), that is hepatitis B virus surface antigen (HBsAg) less than (\<) lower limit of quantitation (LLOQ) and HBV deoxyribonucleic acid (DNA) \<LLOQ sustained for 24 weeks post-GSK3228836 treatment end. In addition, the study will also evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of GSK3228836 in the 4 dosing regimens. This study will assess the efficacy and safety of treatment with GSK3228836 in two populations of participants with CHB; participants on stable nucleos(t)ide treatment (Cohort 1) and participants who are not currently on nucleos(t)ide therapy (Cohort 2). For each population, participants will be randomized into one of the 4 different parallel arms to receive treatment. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately, 440 participants will be enrolled in the study.
Interventions
- DRUG Placebo
- DRUG GSK3228836
- DRUG Nucleos(t)ide therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2022-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04449029
The ClinicalTrials.gov registry entry for NCT04449029 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04449029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04449029 about?
NCT04449029 is a clinical study titled "A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)". Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide therapy. This study is intended to evaluate if treatment with GSK3228836 can a...
What is the current status of trial NCT04449029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 457 participants. The study started on 2020-07-27. Estimated completion is 2022-03-18.
What interventions are being tested in trial NCT04449029?
The interventions under investigation include: Placebo (DRUG), GSK3228836 (DRUG), Nucleos(t)ide therapy (DRUG).
Who is sponsoring clinical trial NCT04449029?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.